COX-2 inhibitors: Exemplars of the drug-safety conundrum

Medical Journal of Australia

Volumn 182, Issue 6, 2005, Pages 262-263

  Nelson, Mark R ^a   Tonkin, Andrew M ^b   Cicuttini, Flavia M ^b   McNeil, John J ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; HORMONE DERIVATIVE; NAPROXEN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; ROFECOXIB; SALICYLIC ACID; VALDECOXIB;

AUSTRALIA; BLEEDING; BLOOD DYSCRASIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON POLYP; COLORECTAL DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; GASTRITIS; HEALTH CARE SYSTEM; HEPATITIS; HIGH RISK PATIENT; HUMAN; LICENCE; LONG TERM CARE; MEDICARE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; PATIENT INFORMATION; RECTUM POLYP;

EID: 15844407507     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06695.x     Document Type: Editorial

References (13)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
2. Bresalier RS, Sandler RS, Hui Quan, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 15 Feb. [Epub ahead of print]. Available at: http://content.nejm.org/cgi/content/abstract/NEJMoaO5O493 (accessed Feb 2005).
3. US Food and Drug Administration. Center for Drug Evaluation and Research. FDA Alert for Practitioners on Celebrex (celecoxib). FDA ALERT 12/17/04. Available at: www.fda.gov/cder/drug/infopage/celebrex/ celebrex-hcp.htm (accessed Jan 2005).
4. US Food and Drug Administration. Center for Drug Evaluation and Research. Naproxen information. Available at: www.fda.gov/cder/drug/ infopage/naproxen/default.htm (accessed Jan 2005).
5. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 15 Feb. [Epub ahead of print]. Available at: http://content.nejm.org/cgi/content/abstract/NEJMoa050405 (accessed Feb 2005).
6. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 15 Feb. [Epub ahead of print]. Available at: http://content.nejm.org/cgi/content/abstract/NEJMoa050330 (accessed Feb 2005).
7. Mukherjee D, Nissen S, Topol E. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
8. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
9. Nelson M, McNeil J, Reid C, Krum H. Factors influencing family physician adherence to hypertension treatment guidelines recommendations on the initiation of pharmacotherapy. Questionnaire survey. Am J Cardiovasc Drugs 2003; 3: 437-441.
10. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321: 406-412.
11. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Writing Group for the Women's Health initiative Investigators. JAMA 2002; 288: 321-333.
12. Graham DJ, Campen D, Cheetham C, et al. Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 2004; 13: S287-S288.
13. Nelson RC, Palsulich B, Gogolak V. Good pharmacovigilance practices: technology enabled. Drug Saf 2002; 25: 407-414.